A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).

Authors

Andrew X. Zhu

Massachusetts General Hospital Cancer Center, Boston, MA

Andrew X. Zhu , Peter R. Galle , Masatoshi Kudo , Richard S. Finn , Ling Yang , Paolo Abada , Josep M. Llovet

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 Gastrointestinal Cancers Symposium

bookmark_border

A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).

First Author: Andrew X. Zhu

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.

First Author: Ian Chau

insert_chart_outlined

Poster

2020 Gastrointestinal Cancers Symposium

bookmark_border

Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2).

First Author: Maria Reig

insert_chart_outlined

Poster

2019 Gastrointestinal Cancers Symposium

bookmark_border

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).

First Author: Masatoshi Kudo